Figure_2.tif (3.33 MB)
In vivo application of MZC does not compromise epithelial integrity or increase HSV-2 susceptibility.
figure
posted on 2014-04-16, 04:16 authored by Larisa Kizima, Aixa Rodríguez, Jessica Kenney, Nina Derby, Olga Mizenina, Radhika Menon, Samantha Seidor, Shimin Zhang, Keith Levendosky, Ninochka Jean-Pierre, Pavel Pugach, Guillermo Villegas, Brian E. Ford, Agegnehu Gettie, James Blanchard, Michael Piatak Jr, Jeffrey D. Lifson, Gabriela Paglini, Natalia Teleshova, Thomas M. Zydowsky, Melissa Robbiani, José A. Fernández-RomeroA) HSV-2 enhancement model. Balb/C mice (n = 40 per group) were depo-treated 7 d before starting vaginal application of each formulation daily for 7 d, followed by HSV-2 G challenge 12 h post-last gel. Percent of uninfected animals over time is shown (*P<0.05 vs. D-PBS, Fisher's exact test). B) Epithelial integrity testing. Depo-treated (vaginal dosing) and fasted (rectal dosing) mice were treated with MZC, D-PBS, or Gynol II. At 1, 6 and 24 h post-application, mice were euthanized, and the entire reproductive or rectal tract was surgically excised for morphological analysis. Pictures (20× magnification) are representative of six sections from two to three animals per group.
History
Usage metrics
Categories
Keywords
microbiologyMedical microbiologyMicrobial pathogensViral pathogensImmunodeficiency viruseshivMicrobial controlantimicrobialsantiviralsAnimal models of infectionVirologyorganismsanimalsvertebratesmammalsprimatesmonkeysOld World monkeysmacaqueInfectious diseasesInfectious disease controlSexually transmitted diseasesViral diseasesPublic and occupational healthpreventive medicineHIV preventionModel organismsAnimal modelsMouse modelsmzcepithelialhsv-2
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC